HR and breast carcinoma: Ribociclib + AI is the preferred treatment for patients with HR+/HER2– advanced breast cancer who have been either diagnosed de novo in the advanced setting or who have relapsed with the advanced disease more than 12 months after completing adjuvant ET for earlier stage disease (either tamoxifen or AI).